Staar Surgical Co Dossier
Qualitative Analysis
Business overview
STAAR Surgical Company designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. The company is the global leader in phakic intraocular lenses (IOLs) with its EVO family of Implantable Collamer Lenses (EVO ICL). These lenses are designed to correct visual disorders such as myopia, hyperopia, astigmatism, and presbyopia, providing an alternative to traditional laser vision correction (like LASIK) and contact lenses or glasses. STAAR sells its products directly in major markets including the United States, Japan, Germany, Spain, Singapore, Canada, and the United Kingdom, and utilizes independent distributors in other regions, most notably China, which historically represents approximately half of the company's consolidated net sales.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding production capacity at the Nidau, Switzerland facility to manufacture and ship 100% of the EVO and EVO+ lenses destined for the Chinese market.
Expected impact: Complete avoidance of import tariffs on Chinese shipments, leading to improved unit costs and gross margin expansion toward the 75%-80% long-term target.
Launching and driving surgeon adoption of the premium EVO+ Implantable Collamer Lens (ICL) in China, the company's largest market.
Expected impact: Higher average selling prices (ASP) and robust volume recovery following the normalization of distributor inventory levels.
Implementing and rolling out a new Oracle Enterprise Resource Planning (ERP) system globally to modernize operations and supply chain management.
Expected impact: Enhanced operational efficiency, better inventory visibility, and streamlined global supply chain coordination.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Following the termination of the Alcon merger, STAAR entered into a cooperation agreement with its largest shareholder, Broadwood Partners, L.P. This agreement led to the appointment of Broadwood's Neal Bradsher and Richard LeBuhn, and Yunqi Capital's Christopher Wang, to STAAR's Board of Directors to oversee capital stewardship and strategic execution.
Terms: No direct financial transaction terms; focused on board representation and corporate governance alignment.